<DOC>
	<DOC>NCT01511692</DOC>
	<brief_summary>This trial is conducted in Europe and Oceania. The aim of this trial is to assess the effects of liraglutide on energy intake in subjects with type 2 diabetes.</brief_summary>
	<brief_title>Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes mellitus Diettreated subjects and/or subjects with type 2 diabetes in OAD (oral antidiabetic drug) monotherapy HbA1c for diettreated subjects: HbA1c between 6.510.0% (both inclusive) and for OAD treated subjects: HbA1c between 6.59.5% (both inclusive) Body mass index (BMI) between 2740 kg/m^2 (both inclusive) Subjects should have a stable body weight for at least 3 months prior to screening (as documented by a weight within 3 to 6 months, prior to screening that is within 15% of the screening weight) Euthyroid subjects Subjects should be unrestrained eaters Recurrent severe hypoglycaemia Impaired liver function Impaired renal function Cardiac problems Uncontrolled treated/untreated hypertension Known or suspected allergy to trial products or related products Use of any drug (except for OADs), which in the investigator's opinion could interfere with the subject's glucose level or body weight Active hepatitis B and/or active hepatitis C Positive HIV (human immunodeficiency virus) antibodies Known or suspected abuse of alcohol or narcotics Habitual excessive consumption of methylxanthinecontaining beverages and foods (coffee, tea, cola drinks, chocolate) as judged by the Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>